TICKERNERD
Menu
AVRAVRHealthcare · Medical Instruments & Supplies

AVR Stock Forecast: Anteris Technologies Global Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$8.97
−3.03% on the day

The 3 Wall Street analysts covering Anteris Technologies Global Corp. hold a median 12-month price target of $15 — +67.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$874.1M
Ticker Nerd rank
21 / 100
Median analyst target
$15
Analysts covering
3
Total return, dividends reinvested
1W
−4.6%
1M
+5.7%
YTD
+79.8%
1Y
+134.8%
From 52W high
−15.1%
From 52W low
+165.4%
$3
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AVR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Anteris Technologies Global Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
88
Growth
71
Size
47
Accruals
42
Revisions
31
Issuance
19
Value
19
Volatility
15
Quality
11

Momentum (88): The shares have been drifting up relative to others.

Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AVR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15Oct 25Jan 26Apr 26Jul 26AVRHigh $16Median $15Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $15Median $15High $16

The green dot is the last close — the median target sits +67.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026Cantor FitzgeraldReiteratesOverweight$15
15 May 2026BarclaysMaintainsOverweight$17 → $18
15 May 2026BarclaysMaintainsOverweight—
27 Mar 2026Cantor FitzgeraldReiteratesOverweight—
12 Mar 2026Cantor FitzgeraldAssumesOverweight$15
11 Mar 2026Wells FargoInitiatesOverweight—
8 Jan 2025Lake StreetInitiatesBuy—
7 Jan 2025BarclaysInitiatesOverweight—
7 Jan 2025Cantor FitzgeraldInitiatesOverweight—
7 Jan 2025TD CowenInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AVR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Anteris Technologies Global Corp. (AVR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.5×

Cheaper than 88% of US stocks

Price / sales
390.4×

Cheaper than 2% of US stocks

Price / book
3.5×

Cheaper than 31% of US stocks

EV / EBITDA
−6.0×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
63.3%

Higher than 89% of US stocks

Earnings growth (YoY)
—
Gross margin
76.9%

Higher than 89% of US stocks

Operating margin
−3072.1%

Higher than 4% of US stocks

Net margin
70.3%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−74.7%

Higher than 16% of US stocks

Return on assets
−42.5%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AVR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
AVRAnteris Technologies Global Corp.$874.1M
21
NNNNAnbio Biotechnology$979.9M
13
STAASTAAR Surgical Co.$1.2B
80
ANGOAngioDynamics, Inc.$648.9M
90
KMTSKestra Medical Technologies Ltd.$1.6B
21
AZTAAzenta, Inc.$1.7B
80
BLFSBioLife Solutions, Inc.$1.8B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Anteris Technologies Global Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVR news & analysis

Anteris Technologies Announces Results for the Second Quarter of 2026

GlobeNewsWire · 11 Aug 2026positive

Anteris Technologies Global Corp. reported its financial results for the quarter ended June 30, 2026, and provided a corporate update. The company announced that it secured U.S. Medicare reimbursement eligibility for its global pivotal PARADIGM Trial under a CMS national coverage policy, enabling reimbursement for eligible procedures at U.S. sites.

Why it matters — The Medicare reimbursement eligibility for the PARADIGM Trial is a significant regulatory milestone that could support the company's U.S. clinical and commercial pathway for its medical device.

FAQ

Frequently asked questions about AVR stock

What is the AVR stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Anteris Technologies Global Corp. have a median 12-month price target of $15, with estimates ranging from $15 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVR stock a buy right now?

Of the 3 analysts covering Anteris Technologies Global Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anteris Technologies Global Corp. 21 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVR?

As at 22 Aug 2026, Anteris Technologies Global Corp. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).

Will AVR stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +67.2% from the last close, and Ticker Nerd's factor model ranks Anteris Technologies Global Corp. 21 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVR stock forecast for 2030?

No analyst covering Anteris Technologies Global Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $16 over the next 12 months.

How has AVR stock performed over the past year?

Anteris Technologies Global Corp. returned +134.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anteris Technologies Global Corp. do?

Anteris Technologies Ltd. is a structural heart company that designs, develops, and commercializes innovative medical devices for treating heart valve diseases.

What is the latest news on AVR?

The most recent item we track (GlobeNewsWire, 11 Aug 2026): "Anteris Technologies Announces Results for the Second Quarter of 2026". Anteris Technologies Global Corp. reported its financial results for the quarter ended June 30, 2026, and provided a corporate update. The company announced that it secured U.S. Medicare reimbursement eligibility for its global pivotal PARADIGM Trial under a CMS national coverage policy, enabling reimbursement for eligible procedures at U.S. sites.

Company

About Anteris Technologies Global Corp.

Anteris Technologies Ltd. is a structural heart company that designs, develops, and commercializes innovative medical devices for treating heart valve diseases. Its flagship product, the DurAVR Transcatheter Heart Valve system, features a single-piece, native-shaped biomimetic design engineered to mimic the performance of a healthy aortic valve, addressing aortic stenosis through minimally invasive procedures. The system incorporates ADAPT anti-calcification tissue, which transforms xenograft material into durable bioscaffolds resembling human tissue, and the ComASUR delivery system, a balloon-expandable mechanism with a reinforced steerable catheter for precise navigation through heart anatomy. Anteris Technologies Ltd. operates across key markets including the United States, Germany, Australia, Switzerland, and Sweden, with a focus on advancing cardiac care via science-driven innovations. Headquartered in Toowong, Australia, the company partners with interventional cardiologists and cardiac surgeons to deliver paradigm-shifting hemodynamic performance and deliverability in transcatheter aortic valve replacement therapies.

CEO Mr. Wayne Geoffrey Paterson · 174 employees · Australia · https://anteristech.com